The combination of CJC-1295 No DAC (Mod GRF 1-29) and Ipamorelin represents one of the most widely investigated dual-peptide paradigms in neuroendocrine research. By simultaneously targeting the growth hormone-releasing hormone (GHRH) receptor and the growth hormone secretagogue receptor (GHSR), this blend allows investigators to evaluate physiological growth hormone release dynamics in vitro and in preclinical animal models.
The combination of CJC-1295 No DAC (Mod GRF 1-29) and Ipamorelin represents one of the most widely investigated dual-peptide paradigms in neuroendocrine research. By simultaneously targeting the growth hormone-releasing hormone (GHRH) receptor and the growth hormone secretagogue receptor (GHSR), this blend allows investigators to evaluate physiological growth hormone release dynamics in vitro and in preclinical animal models.
CJC 1295 no DAC with ipamorelin is a synthetic peptide combination featuring a modified growth hormone-releasing hormone (GHRH 1-29) and a selective growth hormone secretagogue receptor (GHSR) agonist. In preclinical research, this dual-peptide blend is evaluated for its ability to produce synergistic, pulsatile growth hormone (GH) secretion from anterior pituitary somatotrophs without triggering significant spikes in prolactin or cortisol levels.
When evaluating cjc 1295 without dac and ipamorelin, researchers focus on the distinction between modified GHRH formulations and long-acting systemic analogs. CJC-1295 without Drug Affinity Complex (DAC), also known as Modified GRF 1-29, retains a rapid metabolic clearance profile similar to endogenous GHRH. When combined with ipamorelin, a pentapeptide ghrelin receptor agonist, the complex acts via two distinct biochemical cascades, amplifying natural physiological GH pulses rather than inducing continuous GH elevation.
The pharmacological rationale for combining a GHRH analog with a GH secretagogue lies in receptor cross-talk within anterior pituitary somatotroph cells. CJC-1295 No DAC binds to the GHRH receptor, initiating a G-protein-coupled signal transduction pathway that activates adenylyl cyclase, increases intracellular cyclic adenosine monophosphate (cAMP), and stimulates protein kinase A (PKA). This pathway primes somatotrophs for GH synthesis and exocytosis.
Concurrently, Ipamorelin binds selectively to the GHSR-1a (ghrelin receptor). Activation of GHSR-1a triggers the phospholipase C (PLC) pathway, increasing intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilizes calcium ions ($Ca^{2+}$) from the endoplasmic reticulum. In vitro assays demonstrate that co-administration of these two signals produces a supramaximal GH release response that exceeds the additive sum of either peptide administered independently.
Understanding peptide kinetics is vital when establishing laboratory exposure protocols. CJC-1295 with DAC incorporates a reactive lysine residue attached to a maleimide linker, enabling covalent binding to circulating serum albumin. This chemical modification extends the terminal half-life in rodent models from several minutes to over one week, creating continuous elevation of GH and downstream IGF-1 levels.
In contrast, CJC-1295 No DAC lacks this albumin-reactive group. Its half-life in laboratory models is approximately 30 minutes, resulting in distinct, pulsatile spikes in GH concentration that mimic biological secretory patterns. Researchers select CJC-1295 without DAC when studying natural circadian release dynamics, somatostatin inhibition thresholds, and feedback mechanisms within the hypothalamic-pituitary-somatotropic axis.
When designing endo-metabolic research protocols, investigators frequently compare multiple peptides within the secretagogue class. The blend of CJC-1295 No DAC and Ipamorelin provides a unique combination of high selectivity and short half-life, avoiding off-target endocrine activation.
For instance, Sermorelin is the native 29-amino acid sequence of GHRH, but it possesses lower metabolic stability than CJC-1295 No DAC, which features four substituted amino acids (D-Ala2, Gln8, Ala15, and Leu27) that resist enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). On the other hand, Tesamorelin incorporates a trans-3-hexenoic acid group designed specifically for enhanced lipid metabolism assays. Comparing these options highlights why the CJC-1295 No DAC + Ipamorelin pair remains a reference benchmark in cellular research. Researchers interested in broader growth factor signaling pathways also reference our comprehensive growth hormone secretagogues library.
Evaluating a high-purity cjc-1295 no dac + ipamorelin research peptide requires robust analytical documentation to ensure reproducible experimental outcome profiles. Impurities or degraded fragments can misrepresent receptor affinity data or induce cellular toxicity in culture models.
PX1 Research subjects every production lot to strict quality verification standards through independent ISO 17025 accredited laboratories. Each Certificate of Analysis (COA) confirms key technical parameters:
• Purity Profile: Verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to guarantee ≥99.0% purity, ensuring minimal truncated peptide impurities.
• Structural Identity: Confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF to verify exact molecular weight and amino acid sequencing.
• Endotoxin Limits: Tested using Chromogenic LAL assays to verify endotoxin content below 0.01 EU/mg, safe for sensitive cell cultures and in vivo rodent assays.
• US Manufacturing: Synthesized under strict quality controls in USA-based facilities, guaranteeing lot-to-lot consistency and chain-of-custody tracking.
When evaluating suppliers for a cjc-1295 no dac + ipamorelin research peptide, academic institutions and clinical laboratories must avoid unverified grey-market vendors, such as retail sources offering cjc-1295 no dac + ipamorelin jeep peptides or un-analyzed research chemicals. Unverified batches frequently exhibit wide variance in actual peptide concentration, residual trifluoroacetic acid (TFA) salts, and batch-to-batch inconsistency.
PX1 Research serves as a trusted domestic supplier, providing full traceability for laboratory buyers. Whether purchasing single vials for preliminary pilot experiments or establishing long-term supply agreements via our wholesale lab portal, researchers receive consistent, high-purity lyophilized material accompanied by complete lot-specific analytical reports.
To preserve peptide integrity and prevent peptide aggregation, laboratory personnel should follow standardized reconstitution protocols. Lyophilized CJC-1295 No DAC and Ipamorelin are supplied as sterile, vacuum-sealed cakes that require proper solvent selection and careful mechanical handling.
Reconstitution should be performed using laboratory-grade bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on assay requirements. Solvent should be introduced slowly along the glass wall of the vial without direct forceful jetting onto the lyophilized cake. Gentle swirling is recommended; mechanical shaking or vortexing must be avoided to prevent denaturation of secondary structures.
For long-term storage, un-reconstituted lyophilized vials should be stored in deep-freeze conditions at -20°C or -80°C, protected from light exposure. Once reconstituted, solutions should be aliquoted to avoid repeated freeze-thaw cycles and maintained at 2°C to 8°C. Under these conditions, reconstituted peptide solutions typically retain stability for up to 30 days. For further reconstitution calculations, consult our research knowledge base.
Preclinical studies evaluating CJC-1295 No DAC paired with Ipamorelin focus on several biochemical downstream markers. In rodent primary pituitary cell cultures, exposure to both compounds leads to rapid intracellular calcium influx, triggering localized exocytosis of GH storage vesicles.
Secondary observations in preclinical animal models include elevated hepatic transcription of Insulin-like Growth Factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3). Because Ipamorelin exhibits negligible affinity for dopamine, serotonin, or glucocorticoid receptors, these studies demonstrate zero significant fluctuations in plasma cortisol or ACTH concentrations, isolating somatotropic activity from general stress response pathways.
Maintaining uninterrupted research workflows requires reliable logistics and fast transit times. PX1 Research operates centralized shipping hubs located in California and Arizona, allowing same-day dispatch for orders confirmed Monday through Friday before 3:00 PM PST.
Every shipment is packed in cold-chain compatible insulated packaging to prevent temperature degradation during transit. Investigators can explore our full catalog of research compounds by visiting the PX1 product directory or submitting a specialized query to our scientific support team.
What is cjc 1295 no dac with ipamorelin?
CJC 1295 no dac with ipamorelin is a dual-peptide combination featuring a modified growth hormone-releasing hormone analog (Mod GRF 1-29) and a selective growth hormone secretagogue receptor agonist (Ipamorelin), studied together in preclinical models to evaluate synergistic pulsatile growth hormone release.
How does cjc 1295 without dac and ipamorelin work synergistically in vitro?
CJC 1295 without DAC activates the GHRH-R pathway to stimulate cAMP and PKA, while Ipamorelin activates the GHSR-1a pathway to mobilize intracellular calcium ($Ca^{2+}$). Combined, these distinct cascades produce a synergistic increase in growth hormone exocytosis higher than either compound alone.
What distinguishes a cjc-1295 no dac + ipamorelin research peptide from CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex maleimide linker, giving it a short half-life (~30 minutes) that replicates natural physiological GH pulses. CJC-1295 With DAC binds to serum albumin, extending its half-life to several days and producing continuous baseline GH elevation.
How does PX1 Research compare to sources offering cjc-1295 no dac + ipamorelin jeep peptides?
Unlike generic online vendors or unverified retail brands such as jeep peptides, PX1 Research manufactures all compounds in US-based GMP-compliant facilities. Every lot undergoes rigorous HPLC and mass spectrometry testing with public ISO 17025 COAs guaranteeing ≥99% purity and endotoxin levels <0.01 EU/mg.
What purity levels are required for CJC-1295 No DAC and Ipamorelin research?
Laboratory research standards require a minimum purity of ≥98.0%, with high-tier suppliers like PX1 Research providing ≥99.0% purity as verified by analytical RP-HPLC and mass spectrometry.
How should CJC-1295 No DAC + Ipamorelin be reconstituted for lab experiments?
The lyophilized cake should be reconstituted using sterile bacteriostatic water or normal saline. The diluent should be introduced gently down the inner glass wall of the vial and swirled softly without vortexing or shaking.
What storage conditions maintain stability for reconstituted CJC-1295 No DAC + Ipamorelin?
Reconstituted solutions should be stored at 2°C to 8°C (refrigerated) and protected from light, maintaining chemical stability for up to 30 days. Lyophilized powder should be kept at -20°C for long-term storage.
Does CJC-1295 No DAC with Ipamorelin affect cortisol or prolactin levels in preclinical models?
In vitro and animal model data indicate that Ipamorelin is highly selective for GHSR-1a and does not significantly stimulate ACTH, cortisol, prolactin, or aldosterone secretion.
Why is third-party HPLC and Mass Spectrometry testing necessary for secretagogue blends?
Independent HPLC verifies the exact percentage of active peptide without degraded byproducts, while Mass Spectrometry confirms correct amino acid sequences and molecular weight, ensuring experimental reproducibility.
What are the endotoxin limits for PX1 Research secretagogue peptides?
PX1 Research verifies that all research peptides maintain endotoxin levels below 0.01 EU/mg via LAL testing, ensuring compatibility with cell culture models and sensitive preclinical assays.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.